Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger MYND domain-containing protein 12 (ZMYND12) is a previously uncharacterized protein containing a MYND-type zinc finger domain, expressed predominantly in the testis and playing a critical role in the structure and function of the sperm flagellum[1][4]. ZMYND12 localizes to the axoneme of the sperm flagellum, where it forms a complex with other axonemal proteins, such as TTC29 and DNAH1, and is essential for the proper assembly and stability of several flagellar components including the inner dynein arms and the calmodulin- and spoke-associated complex (CSC)[1][4]. Bi-allelic loss-of-function variants in ZMYND12 cause severe axonemal disorganization, leading to the MMAF phenotype and male infertility in humans; analogous phenotypes have been observed in model organisms[1][4]. ZMYND12's activity appears limited to ciliated/flagellated cell structures and no therapeutic targeting or biomarker roles are currently reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger MYND domain-containing protein 12 (ZMYND12).